Glenmark Pharmaceuticals Ltd has received tentative approval by the United States Food and Drug Administration (USFDA) for Nentenab Capsules, 100 mg and 150 mg, the generic version of Ofev@1 Capsules, 100 mg and 150 mg, of Beohringer Ingelheim Pharmaceuticals, Inc.
According to IQVIA sales data for the 10 month period ending April 2021, the Ofev@1 Capsules, 100 mg and 150 mg market achieved annual sales of approximately $1.6 billion.
Glenmark’s current portfolio consists of 172 products authorized for distribution in the U.S. marketplace and 44 ANDA’s pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
Turmeric, widely revered for its vibrant yellow hue and medicinal properties, is an essential ingredient…
In recent discussions about health and nutrition, seed oils—derived from sources like sunflower, soybean, corn,…
For anyone, fruits are often the go-to choice for adding vitamins, minerals, and natural antioxidants…
Air Pollution: Do you know how seriously air pollution can affect your health? Recent studies…
Learn how to safely manage Vitamin D supplementation and avoid toxicity with our expert advice.…
Discover how to break your fast with the right foods to enhance digestion and avoid…